Caribou aligns with FDA on ANTLER-3 phase 3 vispa-cel trial design in 2L LBCL

• Caribou Biosciences in Q1 2026 aligned with FDA on design for ANTLER-3, a randomized pivotal phase 3 study of off-the-shelf CD19 CAR-T candidate vispa-cel in second-line large B cell lymphoma patients who are not candidates for transplant or autologous CAR-T.
• Trial sets up a head-to-head readout versus standard regimens, with progression-free survival as primary endpoint, positioning vispa-cel for a potential registrational path in a population with limited access to curative-intent options.
• Earlier vispa-cel phase 1 findings were already disclosed in November 2025, with additional follow-up slated for presentation at a medical conference in 2026.
• CB-011, an allogeneic BCMA CAR-T for relapsed or refractory multiple myeloma, continues enrolling in phase 1 dose expansion, supported by RMAT status granted March 31, 2026.
• Longer follow-up from CB-011 dose escalation plus initial dose expansion updates will be presented in 2026, with emphasis on durability and depth of responses rather than new technical detail.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caribou Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605071605PRIMZONEFULLFEED9715783) on May 07, 2026, and is solely responsible for the information contained therein.